YIR017W-A Antibody

What is the YIR017W-A antibody and what is its target?

The YIR017W-A antibody is a rabbit polyclonal antibody developed against recombinant Saccharomyces cerevisiae (Baker's yeast) YIR017W-A protein. It is supplied in liquid form with 50% glycerol and 0.01M PBS (pH 7.4) buffer containing 0.03% Proclin 300 as a preservative. This antibody specifically recognizes the YIR017W-A protein in Saccharomyces cerevisiae strain ATCC 204508/S288c and is purified using antigen affinity methods . This type of antibody preparation is typical of research-grade reagents aimed at specific protein detection in model organisms.

What applications is the YIR017W-A antibody validated for?

The YIR017W-A antibody has been tested and validated for enzyme-linked immunosorbent assay (ELISA) and Western blotting (WB) applications . These validation tests are essential as antibody performance can vary significantly across different applications. As demonstrated by YCharOS studies with other antibodies, performance in one application does not necessarily predict performance in another, making application-specific validation crucial . Researchers should conduct preliminary validation experiments before using this antibody in alternative applications beyond those specified.

How should the YIR017W-A antibody be stored and handled?

This antibody should be stored at -20°C or -80°C upon receipt. Repeated freeze-thaw cycles should be avoided to maintain antibody integrity and performance . This storage recommendation is consistent with best practices for preserving antibody function, as freeze-thaw cycles can lead to antibody degradation, aggregation, and loss of specificity or sensitivity. For working solutions, aliquoting the antibody into single-use volumes is recommended to prevent repeated freezing and thawing of the stock solution.

What controls should be used when working with the YIR017W-A antibody?

Based on rigorous antibody validation principles, genetic controls are most recommended:

• Positive control: Wild-type Saccharomyces cerevisiae (strain ATCC 204508/S288c) expressing the YIR017W-A protein

• Negative control: YIR017W-A knockout strains of the same yeast

This approach follows the genetic validation pillar identified by the International Working Group for Antibody Validation, which emphasizes eliminating or significantly reducing target protein expression through genome editing . YCharOS studies have demonstrated that antibodies with genetic control data provided by vendors showed stronger correlation with better performance, particularly in Western blot applications .

How can cross-reactivity of the YIR017W-A antibody be assessed and minimized?

Cross-reactivity assessment requires a multi-step approach:

• Sequence homology analysis: Identify proteins with sequence similarity to YIR017W-A in your experimental system

• Epitope mapping: Determine which regions of YIR017W-A the antibody recognizes

• Validation testing: Test the antibody against:

  • YIR017W-A knockout strains (primary negative control)

  • Strains expressing homologous proteins

  • Non-yeast species samples where appropriate

Recent studies examining Y chromosome-encoded gene antibodies found that only 2 out of 65 antibodies included disclaimers about potential cross-reactivity with homologous proteins . This highlights the importance of researcher-initiated cross-reactivity testing. For polyclonal antibodies like YIR017W-A antibody, cross-reactivity risk may be higher due to recognition of multiple epitopes compared to monoclonal alternatives.

What factors affect reproducibility when using the YIR017W-A antibody in Western blotting?

Reproducibility challenges with antibodies in Western blotting can be addressed through standardization of multiple parameters:

YCharOS open characterization data has shown that even well-characterized antibodies can perform differently under varying conditions, with Western blot generally showing better performance than immunofluorescence applications . For maximum reproducibility, detailed documentation of all protocol parameters is essential.

How can machine learning approaches enhance antibody-antigen binding prediction for YIR017W-A antibody?

Recent developments in machine learning for antibody-antigen binding prediction offer promising approaches:

• Library-on-library screening: Testing YIR017W-A antibody against multiple potential antigens to identify specific binding pairs

• Active learning algorithms: Novel strategies have shown up to 35% reduction in required antigen mutant variants for accurate binding prediction and acceleration of the learning process by approximately 28 steps compared to random labeling approaches

• Out-of-distribution prediction: Crucial for predicting binding to variants not included in training data—particularly important for antibodies like YIR017W-A where natural variants may exist

These computational approaches can supplement experimental validation and potentially reduce the resources needed for comprehensive antibody characterization. When applied to YIR017W-A antibody research, these methods could identify potential cross-reactivity with related yeast proteins or predict binding to protein variants.

What methods can validate the specificity of YIR017W-A antibody beyond standard Western blot?

Comprehensive validation requires multiple orthogonal approaches:

• Immunoprecipitation followed by mass spectrometry:

  • Captures antibody-bound proteins from lysate

  • Identifies all proteins pulled down, revealing potential off-target binding

  • Quantifies relative abundance of target versus non-target proteins

• Genome-wide CRISPR screening:

  • Systematically identifies genes affecting antibody binding

  • Can reveal unexpected dependencies or cross-reactivities

• Epitope mapping:

  • Peptide arrays to identify specific binding regions

  • Alanine scanning mutagenesis to identify critical binding residues

  • Helps predict potential cross-reactive proteins with similar epitopes

YCharOS characterization has demonstrated that antibody selectivity in Western blot should not be used as evidence of selectivity in other applications such as immunofluorescence or immunoprecipitation . Each application requires independent validation.

How should experiments be designed to account for potential YIR017W-A antibody limitations?

Robust experimental design must incorporate multiple controls and validation steps:

• Biological replicates: Minimum of three independent experiments

• Technical replicates: Multiple measurements within each experiment

• Positive controls: Wild-type yeast strains with confirmed YIR017W-A expression

• Negative controls:

  • YIR017W-A knockout strains

  • Non-target organisms/cells

  • Secondary antibody-only controls

• Concentration gradients: Testing multiple antibody dilutions to establish optimal signal-to-noise ratio

• Alternative methods: Confirming key findings with non-antibody-based methods (e.g., mass spectrometry, RNA-seq)

Studies have shown that antibody performance can vary significantly, with YCharOS data indicating that recombinant antibodies often outperform polyclonal antibodies in terms of specificity and reproducibility . Considering this polyclonal nature of the YIR017W-A antibody, rigorous controls become even more critical.

What quantitative approaches can assess YIR017W-A antibody binding characteristics?

Quantitative assessment of binding characteristics provides valuable insights:

• Surface Plasmon Resonance (SPR):

  • Measures real-time binding kinetics (kon and koff)

  • Determines equilibrium dissociation constant (KD)

  • Typical high-affinity antibodies show KD values in the nanomolar to picomolar range

• Bio-Layer Interferometry (BLI):

  • Alternative to SPR for kinetic measurements

  • Suitable for high-throughput screening

  • Can assess binding to multiple antigens simultaneously

• Isothermal Titration Calorimetry (ITC):

  • Provides complete thermodynamic profile

  • Measures binding stoichiometry in solution

  • Determines enthalpy and entropy contributions to binding

These quantitative approaches provide deeper insights beyond simple positive/negative binding results and help establish meaningful comparisons between different antibody preparations or lots.

What strategies address weak or absent signal when using YIR017W-A antibody?

Systematic troubleshooting approaches include:

YCharOS studies have demonstrated that even well-characterized antibodies can perform poorly across different applications, with only a small percentage showing consistent results across techniques . This highlights the importance of application-specific optimization when working with antibodies like YIR017W-A.

How can background issues be addressed when using the YIR017W-A antibody?

High background signal can obscure specific results and requires systematic optimization:

• Blocking optimization:

  • Increase blocking time (2-4 hours or overnight)

  • Test different blocking agents (5% BSA, 5% milk, commercial blockers)

  • Add 0.1-0.3% Tween-20 to washing and antibody incubation buffers

• Antibody dilution:

  • Test a dilution series (typically starting at 1:500 up to 1:5000)

  • Reduce incubation time or temperature if necessary

• Washing optimization:

  • Increase wash duration (5 x 5 minutes instead of standard 3 x 5)

  • Use higher detergent concentration in wash buffers

  • Consider alternative detergents (Triton X-100 instead of Tween-20)

• Sample preparation:

  • Pre-clear lysates with Protein A/G beads

  • Pre-absorb antibody with cells/tissue lacking target

YCharOS reports have indicated that background issues are particularly common in immunofluorescence applications compared to Western blot , suggesting that each application may require distinct optimization approaches.

How should researchers interpret unexpected banding patterns in Western blots using YIR017W-A antibody?

• Post-translational modifications:

  • Phosphorylation typically shifts bands 5-10 kDa higher

  • Glycosylation can cause significant shifts (10+ kDa) and band smearing

  • Ubiquitination adds approximately 8.5 kDa per ubiquitin moiety

• Proteolytic processing:

  • Compare with predicted cleavage sites

  • Test protease inhibitor cocktails during sample preparation

• Splice variants:

  • Cross-reference with known transcript variants

  • Confirm with RT-PCR targeting specific isoforms

• Cross-reactivity:

  • Compare with YIR017W-A knockout controls

  • Consult sequence databases for homologous proteins

YCharOS data has shown that selective antibodies may display multiple bands in wild-type samples due to factors such as splice isoforms, multimers, or post-translationally modified forms of the target protein . Documentation of all observed bands with molecular weights is essential for complete reporting.

What statistical approaches are appropriate for quantifying YIR017W-A antibody experimental results?

Robust statistical analysis enhances research rigor:

• Western blot densitometry:

  • Normalize to loading controls (e.g., GAPDH, actin)

  • Use linear range of detection for quantification

  • Apply appropriate statistical tests (t-test for two conditions, ANOVA for multiple)

• ELISA quantification:

  • Generate standard curves with purified protein

  • Use 4 or 5-parameter logistic regression for curve fitting

  • Report both technical and biological variability

• Outlier analysis:

  • Apply Grubbs' test or ROUT method to identify outliers

  • Document all exclusion criteria before analysis

  • Report all excluded data points in publication

• Sample size determination:

  • Conduct power analysis prior to experiments

  • Aim for statistical power of at least 0.8

  • Report confidence intervals along with p-values

Proper statistical approaches are essential as antibody-based techniques can exhibit significant variability, particularly with polyclonal antibodies that may recognize multiple epitopes with different affinities.